Antonio Gallo (France)

University of Paris Department of Endocrinology and Metabolism

After completing his training in Internal Medicine at Sapienza University of Rome, Dr Gallo obtained a PhD in Physiology, Physiopathology and Therapeutics at Sorbonne University. He works as a consulting physician at Pitié-Salpêtrière Sorbonne University Hospital. His clinical activity is focused on the management of genetic dyslipidaemias, as well as cardiovascular risk work-up of subjects with cardiovascular risk factors in primary prevention. His research interests include lipid metabolism, severe forms of genetic dyslipidaemias, especially familial hypercholesterolemia and familial hyperchylomicronaemia syndrome, residual risk in primary and secondary prevention, and imaging in atherosclerosis. His current projects are focused on vascular calcifications in familial hypercholesterolemia and their role in cardiovascular risk restratification and prediction, retinal microvascular remodeling in cardiometabolic disease, and Lp(a) as a marker of residual cardiovascular risk. He is principal investigator of two ongoing studies on familial hypercholesterolemia and has participated to several pharmacological phase 3 trials on novel treatments in Homozygous Familial Hypercholesterolemia. He has authored or co-authored more than 30 peer-reviewed publications. He is a member of EAS and French Atherosclerosis Society NSFA, ESH and VASCAGENET Cost action.

Author Of 1 Presentation

Conference Calendar

O070 - Coronary Artery Calcium score and SAFEHEART-Risk Equation for risk stratification in primary prevention familial hypercholesterolemia. (ID 173)

Session Type

Vascular Biology

Session Name

Workshop: Imaging the vulnerable plaque (ID 13)

Session Time

17:00 - 18:30

Date

Wed, 02.06.2021

Room

Live Streamed

Lecture Time

17:41 - 17:49

Presenter

Antonio Gallo (France)

Abstract

Abstract

Background and Aims

Common cardiovascular risk equations are imprecise for heterozygous Familial Hypercholesterolemia (HeFH). Coronary Artery Calcium (CAC) score could help to better stratify the risk of major cardiovascular events (MACE). We investigated the additional contribution of CAC Score to SAFEHEART risk equation (SAFEHEART-RE) for MACE prediction in HeFH.

Methods

We analyzed data from primary prevention HeFH patients undergoing CAC quantification from two ongoing national registries , REFERCHOL and SAFEHEART. CAC score was expressed as log(CAC + 1).We used probability-weighted Cox proportional hazard models to estimate hazard ratios (HR). Area under the receiver operator characteristic curve (AUC) and net reclassification improvement (NRI) were used to compare incremental contribution of CAC score to SAFEHEART-RE for MACE prediction. MACE were defined as coronary heart disease, stroke or transient ischemic attack, peripheral artery disease, resuscitated sudden death and cardiovascular death.

Results

We included 1424 patients (age 48.9±12.8, men 45.9%).

After a 2.4-years follow-up, MACE occurred in 70 subjects. The addition of log(CAC+1) to SAFEHEART-RE was associated with an improved prediction of MACE in intermediate-risk (from HR 3.2 [95%CI 1.77-5.59] to HR 8.18 [95%CI 3.26-20.37]) and in high-risk subjects (from HR 3.5 [95%CI 1.93-6.30] to HR 20.21 [95%CI 8.58-47.6]) (log-rank p <0.0001). The c-statistics confirmed a significant improvement in MACE prediction by the addition of log(CAC+1) to SAFEHEART-RE (AUC 0.896 [0.889-0.903]) versus SAFEHEART-RE alone (AUC 0.859 [0.852-0.866]) (p= 0.004). The addition of CAC score was associated with an overall NRI of 46.8%.

table and figure.png